Drug Profile
Soquelitinib - Corvus Pharmaceuticals
Alternative Names: CPI-818Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Corvus Pharmaceuticals
- Developer Angel Pharmaceuticals; Corvus Pharmaceuticals
- Class 1 ring heterocyclic compounds; Amides; Antineoplastics; Antiretrovirals; Antivirals; Benzene derivatives; Cyclopropanes; Ethers; Ketones; Small molecules; Sulfides; Thiazoles
- Mechanism of Action Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II T-cell lymphoma
- Phase I Atopic dermatitis; T-cell leukaemia
- Preclinical Autoimmune disorders; Graft-versus-host disease; HIV infections; Hypersensitivity; Lymphoproliferative disorders; Solid tumours